MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Ken H. Young, Zijun Y. Xu‐Monette et al.|Blood|2013Cited by 677
Plasma cells require autophagy for sustainable immunoglobulin productionNiccolò Pengo, Simone Cenci, Maria Scolari et al.|Nature Immunology|2013Cited by 417
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y. Xu‐Monette, Ken H. Young, Karen Dybkær et al.|Blood|2012Cited by 390
Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesisMarieta Cagánová, Stefano Casola, Chiara Carrisi et al.|Journal of Clinical Investigation|2013Cited by 255
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Ken H. Young, Zijun Y. Xu‐Monette et al.|Blood|2013Cited by 246